Feature | November 24, 2014

Long-term Anti-clotting/antiplatelet Drug Combo in AFib Patients May Raise Risk of Dementia

Researchers found that atrial fibrillation patients taking warfarin were more likely to develop dementia if lab measurements of their clotting time were frequently too or too fast

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Photo courtesy of American Stroke Association


November 16, 2014 — Long-term overtreatment with the anti-clotting drug warfarin, combined with antiplatelet therapy of aspirin or clopidigrel to prevent stroke, may raise the risk of dementia in people with atrial fibrillation, according to research presented at the American Heart Association’s Scientific Sessions 2014.

Researchers studied 1,031 patients with no previous history of stroke or dementia for up to 10 years while on the drug combination. After adjusting for traditional stroke and bleeding risk factors, patients who had abnormally slow blood clotting times — International Normalized Ratio (INR) measurement above 3 — on 25 percent or more of their monitoring tests were more than twice as likely to be diagnosed with dementia than patients whose tests showed overtreatment less than 10 percent of the time. The increase is higher than what researchers found in a previous study of warfarin alone.

Patients who had abnormally slow clotting times were considered to be receiving too much medication.

Researchers previously found that atrial fibrillation patients taking warfarin were more likely to develop dementia if lab measurements of their clotting time were frequently too slow or too fast. From those results they concluded that brain injury from both small bleeds and clots was important in the development of dementia in atrial fibrillation patients.

If you’re taking warfarin and an antiplatelet drug such as aspirin or clopidgrel, check with your doctor to make sure you need one or both of the long-term antiplatelet medications, Bunch said.

Most patients in the study were Caucasian; researchers aren’t sure results would apply to other ethnic groups.

For more information: www.heart.org


Additional Content

News | Cardiovascular Clinical Studies

Nov. 1, 2026 – Abbott has announced the 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular ...

Home November 03, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 27, 2026 — Atrium Therapeutics, developer of RNA therapeutics targeted to the heart, has announced that the first ...

Home October 30, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 1, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the first patient enrollment in the IBE ...

Home October 01, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 31, 2026 — Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk ...

Home September 02, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2026 — A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had ...

Home August 21, 2026
Home
Subscribe Now